Edition:
India

Omeros Corp (OMER.OQ)

OMER.OQ on NASDAQ Stock Exchange Global Market

19.32USD
13 Dec 2017
Change (% chg)

$0.42 (+2.22%)
Prev Close
$18.90
Open
$18.90
Day's High
$19.48
Day's Low
$18.85
Volume
160,771
Avg. Vol
243,618
52-wk High
$27.07
52-wk Low
$8.73

Select another date:

Tue, Dec 12 2017

BRIEF-Omeros Corporation Announces Fda Approval Of Omidria For Use In Pediatric Patients

* OMEROS CORPORATION ANNOUNCES FDA APPROVAL OF OMIDRIA® FOR USE IN PEDIATRIC PATIENTS

BRIEF-Omeros Corp reports Q3 loss per share $0.16

* Omeros Corporation reports third quarter 2017 financial results

BRIEF-OMEROS REPORTS ADDITIONAL POSITIVE DATA FOR OMS721

* OMEROS REPORTS ADDITIONAL AND CONSISTENTLY POSITIVE DATA FOR OMS721 IN PATIENTS WITH HEMATOPOIETIC STEM CELL TRANSPLANT-ASSOCIATED THROMBOTIC MICROANGIOPATHY

BRIEF-Omeros Corp amends term loan agreement

* On Oct 11, co entered amendment no. 1 to loan agreement, which amended term loan agreement, dated October 26, 2016​

BRIEF-OMEROS ANNOUNCES SETTLEMENT OF INFRINGEMENT SUIT AGAINST ANDA FILER PAR

* OMEROS ANNOUNCES SETTLEMENT OF INFRINGEMENT SUIT AGAINST ANDA FILER PAR

BRIEF-Omeros announces pricing of public offering of common stock

* Omeros announces pricing of public offering of common stock

BRIEF-Omeros announces public offering of common stock

* Says offering 3.00 million common shares Source text for Eikon: Further company coverage:

BRIEF-Omeros Corporation Q2 loss per share $0.33

* Omeros corporation reports second quarter 2017 financial results

BRIEF-FDA grants orphan drug designation to Omeros’ OMS721

* FDA grants Orphan Drug Designation to Omeros’ OMS721 for treatment of IGA Nephropathy

Select another date: